Toleration of high doses of angiotensin-converting enzyme inhibitors in patients with chronic heart failure: results from the ATLAS trial
BM Massie, PW Armstrong, JGF Cleland… - Archives of Internal …, 2001 - jamanetwork.com
Background Treatment with angiotensin-converting enzyme (ACE) inhibitors reduces
mortality and morbidity in patients with chronic heart failure (CHF), but most affected patients …
mortality and morbidity in patients with chronic heart failure (CHF), but most affected patients …
Toleration of high doses of angiotensin-converting enzyme inhibitors in patients with chronic heart failure: results from the ATLAS trial. The Assessment of Treatment …
BM Massie, PW Armstrong, JG Cleland… - Archives of Internal …, 2001 - europepmc.org
Background Treatment with angiotensin-converting enzyme (ACE) inhibitors reduces
mortality and morbidity in patients with chronic heart failure (CHF), but most affected patients …
mortality and morbidity in patients with chronic heart failure (CHF), but most affected patients …
Toleration of high doses of angiotensin-converting enzyme inhibitors in patients with chronic heart failure: results from the ATLAS trial. The Assessment of Treatment …
BM Massie, PW Armstrong… - Archives of internal …, 2001 - pubmed.ncbi.nlm.nih.gov
Background Treatment with angiotensin-converting enzyme (ACE) inhibitors reduces
mortality and morbidity in patients with chronic heart failure (CHF), but most affected patients …
mortality and morbidity in patients with chronic heart failure (CHF), but most affected patients …
[引用][C] Toleration of high doses of angiotensin-converting enzyme inhibitors in patients with chronic Heart failure: Results from the ATLAS trial
BM MASSIE, PW ARMSTRONG… - Archives of internal …, 2001 - pascal-francis.inist.fr
Toleration of high doses of angiotensin-converting enzyme inhibitors in patients with
chronic Heart failure : Results from the ATLAS trial CNRS Inist Pascal-Francis CNRS Pascal …
chronic Heart failure : Results from the ATLAS trial CNRS Inist Pascal-Francis CNRS Pascal …
Toleration of high doses of angiotensin-converting enzyme inhibitors in patients with chronic heart failure-Results from the ATLAS trial
B Massie, P Armstrong, J Cleland, J Horowitz… - 2001 - digital.library.adelaide.edu.au
Background Treatment with angiotensin-converting enzyme (ACE) inhibitors reduces
mortality and morbidity in patients with chronic heart failure (CHF), but most affected patients …
mortality and morbidity in patients with chronic heart failure (CHF), but most affected patients …
Toleration of high doses of angiotensin-converting enzyme inhibitors in patients with chronic heart failure: Results from the ATLAS trial
BM Massie, PW Armstrong… - Archives of …, 2001 - utsouthwestern.elsevierpure.com
Background: Treatment with angiotensin-converting enzyme (ACE) inhibitors reduces
mortality and morbidity in patients with chronic heart failure (CHF), but most affected patients …
mortality and morbidity in patients with chronic heart failure (CHF), but most affected patients …